* Adicet Bio Inc ACET.OQ ACET.O is expected to show a
fall in
quarterly revenue when it reports results on November 8
(estimated).
* The Boston Massachusetts-based company is expected to
report a
90.3% decrease in revenue to $333.33 thousand from $3.43 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Adicet Bio Inc is
for a
loss of 53 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Adicet Bio
Inc is
$27, above its last closing price of $17.87.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.44 -0.45 -0.56 Missed -23.1
Mar. 31 2022 -0.24 -0.18 0.10 Beat 154.9
Dec. 31 2021 -0.25 -0.42 -0.47 Missed -11.6
Sep. 30 2021 -0.44 -0.44 -0.44 Met 0
Jun. -0.53 -0.53 -0.34 Beat 35.8
30 2021
Mar. 31 2021 -0.43 -0.49 -0.82 Missed -67.9
Dec. 31 2020 -0.88 -0.46 Beat 47.7
Sep. 30 2020 -0.81 -0.81 -2.84 Missed -248.5
This summary was machine generated November 5 at 03:13 GMT. All
figures in US dollars unless otherwise stated